ATE424208T1 - Proteinkinaseinhibitoren - Google Patents

Proteinkinaseinhibitoren

Info

Publication number
ATE424208T1
ATE424208T1 AT05744735T AT05744735T ATE424208T1 AT E424208 T1 ATE424208 T1 AT E424208T1 AT 05744735 T AT05744735 T AT 05744735T AT 05744735 T AT05744735 T AT 05744735T AT E424208 T1 ATE424208 T1 AT E424208T1
Authority
AT
Austria
Prior art keywords
angiogenesis
mammal
relates
compounds
protein kinase
Prior art date
Application number
AT05744735T
Other languages
English (en)
Inventor
Catherine Berset
Stephan Audetat
Julia Tietz
Tea Gunde
Alcide Barberis
Andreas Schumacher
Peter Traxler
Original Assignee
Oncalis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncalis Ag filed Critical Oncalis Ag
Application granted granted Critical
Publication of ATE424208T1 publication Critical patent/ATE424208T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05744735T 2004-06-09 2005-06-09 Proteinkinaseinhibitoren ATE424208T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04013572 2004-06-09

Publications (1)

Publication Number Publication Date
ATE424208T1 true ATE424208T1 (de) 2009-03-15

Family

ID=34968638

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05744735T ATE424208T1 (de) 2004-06-09 2005-06-09 Proteinkinaseinhibitoren

Country Status (8)

Country Link
US (1) US20070149535A1 (de)
EP (1) EP1765351B9 (de)
AT (1) ATE424208T1 (de)
AU (1) AU2005251408A1 (de)
CA (1) CA2570073A1 (de)
DE (1) DE602005013085D1 (de)
ES (1) ES2321315T3 (de)
WO (1) WO2005120513A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006125101A2 (en) 2005-05-20 2006-11-23 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
US7893058B2 (en) 2006-05-15 2011-02-22 Janssen Pharmaceutica Nv Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
JP2009538877A (ja) 2006-05-31 2009-11-12 ガラパゴス・ナムローゼ・フェンノートシャップ 変性疾患及び炎症性疾患の治療に有用なトリアゾロピラジン化合物
AR061229A1 (es) * 2006-06-06 2008-08-13 Schering Corp Imidazopirazinas como inhibidores de la proteina quinasa
US20110206607A1 (en) * 2007-05-10 2011-08-25 Roger Olsson Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors
WO2008138842A1 (en) 2007-05-10 2008-11-20 Galapagos N.V. Imidazopyrazines and triazolopyrazine for the treatment of joint degenerative and inflammatory diseases
WO2010083617A1 (en) * 2009-01-21 2010-07-29 Oncalis Ag Pyrazolopyrimidines as protein kinase inhibitors
CA2778949C (en) 2009-10-30 2018-02-27 Janssen Pharmaceutica Nv Imidazo[1,2-b]pyridazine derivatives and their use as pde10 inhibitors
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
EP2723744B1 (de) 2011-06-27 2016-03-23 Janssen Pharmaceutica, N.V. 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]-chinoxalin-derivate
ES2855575T3 (es) 2012-06-26 2021-09-23 Janssen Pharmaceutica Nv Combinaciones que comprenden compuestos de 4-metil-[1,2,4]triazolo[4,3-a]quinoxalina como inhibidores de PDE2 e inhibidores de PDE10 para su uso en el tratamiento de trastornos neurológicos o metabólicos
CA2875057C (en) 2012-07-09 2021-07-13 Janssen Pharmaceutica Nv Imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyrazine compounds and their use as inhibitors of the phosphodiesterase 10 enzyme
US11718622B2 (en) 2020-03-16 2023-08-08 Exelixis Inc. Heterocyclic adenosine receptor antagonists
WO2022164934A1 (en) * 2021-01-26 2022-08-04 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Imidazo[1,2-a]pyrazine and imidazo[1,2-a]pyridine based tyrosyl-dna phosphodiesterase i (tdp1) inhibitors
US11970499B1 (en) 2023-12-22 2024-04-30 King Faisal University Pyrazolo[1,5-c]pyrimidine compounds as CK2 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL355206A1 (en) * 1999-10-08 2004-04-05 Grunenthal Gmbh Bicyclic imidazo-3-yl-amine derivatives
GB0018473D0 (en) * 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
DE10050663A1 (de) * 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
DE10141212A1 (de) * 2001-08-22 2003-03-06 Bayer Ag Neue 4-Aminofuropyrimidine und ihre Verwendung
US20030199525A1 (en) * 2002-03-21 2003-10-23 Hirst Gavin C. Kinase inhibitors
BR0309398A (pt) * 2002-04-19 2005-02-01 Cellular Genomics Inc Composto ou um seu sal, hidrato, solvato, forma cristalina, diastereÈmero, prodroga farmaceuticamente aceitável, ou misturas deles, composição farmacêutica, e, métodos para tratar uma condição envolvida com a cinase em um mamìfero, para tratar câncer, e para identificar uma cinase

Also Published As

Publication number Publication date
CA2570073A1 (en) 2005-12-22
AU2005251408A1 (en) 2005-12-22
WO2005120513A1 (en) 2005-12-22
EP1765351B9 (de) 2010-03-24
EP1765351B1 (de) 2009-03-04
EP1765351A1 (de) 2007-03-28
ES2321315T3 (es) 2009-06-04
US20070149535A1 (en) 2007-06-28
DE602005013085D1 (de) 2009-04-16

Similar Documents

Publication Publication Date Title
ATE424208T1 (de) Proteinkinaseinhibitoren
ATE497496T1 (de) 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
ZA200703002B (en) Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
NO20072558L (no) Mitotiske kineseinhibitorer og fremgangsmater for anvendelse derav
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
TW200510334A (en) Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
HK1135103A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
ATE525375T1 (de) Hemmer von janus-kinasen und/oder 3- phosphoinositid-abhängiger protein-kinase 1
HRP20050533A2 (en) Aminoindazole derivatives and use thereof as kinase inhibitors
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
HK1093159A1 (en) Monocyclic heterocycles as kinase inhibitors
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
ATE419249T1 (de) Inhibitoren von mitotischem kinesin
EA201170344A1 (ru) Азаиндольные ингибиторы iap
MA32183B1 (fr) Pyrimidylcyclopentanes hydroxylés utilisés comme inhibiteurs de protéine kinase akt
BRPI0411864A (pt) combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas
ATE502935T1 (de) C-met-proteinkinasehemmer
ATE494008T1 (de) Verwendung eines p38-kinasehemmers zur behandlung von psychiatrischen erkrankungen
UA86051C2 (en) Substituted quinoline compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1765351

Country of ref document: EP

REN Ceased due to non-payment of the annual fee